Lupus & antiphospholipid syndrome

Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage

Lupus Sci MedPublished Retrospective cohort study

Authors' conclusion

CVD and osteoporosis were more prevalent in SLE than in the general population. The dose and frequency of GC treatment in patients with SLE have decreased over the years. Prednisone usage in doses exceeding 5 mg/day is associated with significantly increased odds of osteoporosis and CVD.

Study context

Population
Patients with systemic lupus erythematosus (SLE) in the computerised database of a large health maintenance organisation, matched with subjects from the general population87.79% women
Participants
1,073 patients
Exposure
Mean daily prednisone dose >5 mg/day vs ≤5 mg/day; SLE vs general population
Outcome
Association between GC cumulative daily doses, HCQ and comorbidities (osteoporosis, CVD, hypertension, diabetes mellitus)
Methodological detailsmatched with general population, multivariable logistic regression, health maintenance organisation database
  • Matched with general population
  • Multivariable logistic regression
  • Health maintenance organisation database

Main finding

As reported in the abstract

Comorbidities by mean daily prednisone dose
  • Increased odds for comorbidities with mean daily prednisone >5 mg/day vs ≤5 mg/day
  • Adjusted for age, sex, socioeconomic status, smoking, disease duration and hydroxychloroquine (HCQ) use

Observational data: associations, not effects.

Further findings

HCQ initiation within 12 months of SLE diagnosis

2000
51.02%
2010
83.67%
2018
93.02%

Annual glucocorticoid (GC) usage

2000
45.34%
2020
30.76%

Cardiovascular disease (CVD) and osteoporosis prevalence, SLE vs general population

More prevalent in SLE than in the general population

Original publication

Real-world treatment patterns in patients with systemic lupus erythematosus: associations with comorbidities and damage. Lupus Sci Med. Published 24 September 2024. doi:10.1136/lupus-2024-001266

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.